Entyvio on Track to Rake in US$2 Billion in FY2018, Ninlaro Eyed as Next Big Seller

Takeda President and CEO Christophe Weber Takeda Pharmaceutical’s ulcerative colitis and Crohn’s disease treatment Entyvio (vedolizumab) is on track to achieve global sales of US$2 billion in the year ending in March 2019, President and CEO Christophe Weber said on...read more